[ad_1]
Stallergenes Greer, a global healthcare company specializing in allergen immunotherapy (AIT), announced the company’s sponsorship by the company entitled “Supporting the needs of individual patients: AIT remains an unparalleled model for allergy personalized medicine” in Kraco (Poland) European Society of Allergy and Clinical Immunology (EAACI) 2021 Congress.
Stallergenes Greer will attend the conference from July 10th to 12th. He will also present nine posters to discuss precision medicine in AIT and announce new data from clinical trials and real-world research.
“By exploring the pathogenesis of each individual, precision medicine provides patients with precise, personalized, and targeted treatment methods, paving the way for the future of allergen immunotherapy.We are proud to present new data in our product portfolio and advance knowledge about allergen immunotherapy to improve the quality of life of allergy sufferers,” said Amer Jaber, executive vice president of European and international operations and president of Stallergenes SAS.
Agenda
Seminar (July 11: 10:00-11:30)
“Support the needs of individual patients: AIT is still an unparalleled personalized medical treatment model for allergies“
Chairperson: Giorgio Walter Canonica, Italy; Ruby Pawankar, Japan; Marek Jutel, Poland
The full story on Benzinga.com
[ad_2]
Source link
